The Dipharma Group is a global Contract Development and Manufacturing Organisation (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCEs), and advanced intermediates for the generic and contract manufacturing markets. With a strong portfolio of approximately 40 APIs with Drug Master Files (DMFs) registered worldwide, Dipharma is well-positioned to meet the evolving needs of the pharmaceutical industry. With a workforce of about 600 skilled and highly committed employees, and equipped with four state-of-the-art CGMP facilities located in the United States and Italy, as well as commercial offices in Italy, the U.S.A., and China, Dipharma has a robust operational infrastructure.

Services include:
- APIs (Active Pharmaceutical Ingredients)
- Contract Development and Manufacturing (CDMO)
- Intermediates
- Fine Chemicals
- Regulatory Services

With a proven track record of successfully navigating inspections by major regulatory agencies, Dipharma is committed to delivering quality and innovation while managing processes efficiently. The company's extensive capabilities ensure it can supply quantities from laboratory to industrial scale, covering the entire lifecycle of pharmaceutical substances. For more information, visit dipharma.com.